Feb 1 (Reuters) - Abbvie Inc ABBV.N
* Health Canada grants priority review to Abbvie's investigational regimen of Glecaprevir/Pibrentasvir (G/P) for the treatment of chronic hepatitis c in all major genotypes (GT1-6) Source text for Eikon: ID:nCNWk0CbFa Further company coverage: ABBV.N